Clinical trials: Negative Symptoms in Schizophrenia
Schizophrenia
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms.
- Trial name
- NCT07122895
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
Transcranial Magnetic Stimulation Repetitive, Schizophrenia
Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms
The major target of the study is to confirm the safety and efficacy of our augmented protocol of theta-burst TMS in schizophrenia.
- Trial name
- tbTMS_SCH21 (NCT05100888)
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- Hungary
- Volunteers
- 76 people
- Sponsor
- Semmelweis University
Schizophrenia and Disorders With Psychotic Features
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms
The purpose of this study is to investigate if minocycline limits the development of negative symptoms in early psychosis and to test via what mechanism of action this change occurs.
- Trial name
- BeneMin (NCT02928965)
- Testing
- Minocycline
- Volunteers
- 207 people
- Sponsor
- University of Manchester
Schizophrenia
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
- Trial name
- NCT01760993
- Testing
- SPD489
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Shire
Schizophrenia
Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women
The aim of the project is to assess the efficacy of Adjunctive Selective Estrogen Receptor Modulators (Raloxifene) on Negative and Cognitive symptoms of Schizophrenia in Postmenopausal Women.
- Trial name
- NCT03418831
- Testing
- Raloxifene Hydrochloride
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Brain Stimulation, Clinical Symptoms and Cognition
The purpose of this study is to test the impact of non-invasive brain stimulation, transcranial direct current stimulation (tDCS), on auditory hallucinations, negative symptoms and cognition in schizophrenia.
- Trial name
- NCT05053451
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Schizophrenia, Negative Type; Schizophrenic
Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia
The main purpose of this study is to learn how transcranial magnetic stimulation (TMS) helps improve negative symptoms of schizophrenia.
- Conditions
- Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
- Trial name
- NCT03648268
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizoaffective Disorder
Clinical Trial of Dipyridamole in Schizophrenia
This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00349973
- Testing
- Dipyridamole, Olanzapine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Maryland, Baltimore
Negative Symptoms in Schizophrenia, Schizophrenia
NST-SPARK: Preliminary Study of an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia
This study evaluates the feasibility and acceptability of a prototype for NST-SPARK (version 1.5). This is an augmented reality (AR) mobile phone application that uses Recovery-oriented Cognitive Therapy (CT-R) to target negative…
- Conditions
- Negative Symptoms in Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NST-SPARK-1b (NCT06653829)
- Testing
- SPARK
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- North Shore Therapeutics, Inc.
Chronic Schizophrenia
Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia
The purpose of this study is to determine whether the use of Nintendo Wii will help improve negative symptoms of Schizophrenia and quality of life of patients with chronic Schizophrenia.
- Trial name
- NCT01761383
- Testing
- Nintendo Wii video console and Nintendo Wii Fit Plus games
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Queen's University
Schizophrenia
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).
- Trial name
- NCT01738698
- Testing
- SPD489 40mg, SPD489 100mg, SPD489 160mg
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shire
Schizophrenia, Schizoaffective Disorder, Mixed Type
Online HD-tDCS Over the Left DLPFC During a Working Memory Task for Treating Negative Symptoms of Schizophrenia
In this randomized double-blind trial, the investigators aim to investigate whether online high definition transcranial direct current stimulation (HD-tDCS) over the left dorsolateral prefrontal cortex (DLPFC) during a working…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Mixed Type, Negative Symptoms in Schizophrenia
- Trial name
- NCT05582980
- Testing
- HD-tDCS
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia, Depression
Characterization of the Motivational Deficit in Schizophrenia and Depression
This research focuses on disorders of motivation, responsible for a disability that patients experience daily. It is a disorder that affects behavior, especially social.
- Trial name
- SCHIZOBAT (NCT02378818)
- Testing
- Force task, preference task, discount task, learning task.
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia, Schizoaffective Disorder
Efficacy of Pregnenolone in Patients With Schizophrenia
Four-month trial of pregnenolone or placebo, as an additional medication, to treat negative symptoms and cognitive decline in schizophrenia.
- Trial name
- NCT00615511
- Testing
- pregnenolone
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Weill Medical College of Cornell University
Schizophrenia, Negative Symptoms
Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia
Negative symptoms in schizophrenia present a challenge to the clinician owing to their poorer response to conventional treatment with antipsychotics.
- Trial name
- RIS-CIT-SCH (NCT00893256)
- Testing
- Risperidone, Citalopram
- Where
- India
- Volunteers
- 48 people
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
Schizophrenia, Schizoaffective Disorder
Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00728728
- Testing
- Dietary Supplement: Pregnenolone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
This is a multicenter, randomized, double-blind, placebo-controlled, three period crossover study to evaluate the effects of RO5545965 on the functioning of key brain circuitry involved in negative symptoms using functional…
- Trial name
- NCT02824055
- Testing
- RO5545965
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms (such as blunted affect, emotional withdrawal, and poor rapport) of schizophrenia.
- Trial name
- NCT00212836
- Testing
- asenapine, olanzapine
- Volunteers
- 481 people
- Sponsor
- Organon and Co
Schizophrenia, Negative Symptoms in Schizophrenia
Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS
This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis), Cognitive Deficit
- Trial name
- NCT06278532
- Testing
- Brief Negative Symptoms Scale, The Calgary Depression Scale for Schizophrenia, The Schizophrenia Cognition Rating Scale
- Where
- 2 sites in Lithuania
- Volunteers
- 200 people
- Sponsor
- Lithuanian University of Health Sciences
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192906
- Testing
- bitopertin [RO4917838]
- Where
- 113 sites in United States, Brazil and 12 more
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche